Correction to: Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis
Adv Ther
.
2024 Jun;41(6):2534-2535.
doi: 10.1007/s12325-024-02858-1.
Authors
Mei Lu
1
2
,
Loralee B Rupp
3
,
Christina Melkonian
4
,
Sheri Trudeau
4
,
Yihe G Daida
5
,
Mark A Schmidt
6
,
Stuart C Gordon
7
8
Affiliations
1
Department of Public Health Sciences, Henry Ford Health, One Ford Place, Detroit, MI, 48202, USA. mlu1@hfhs.org.
2
Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, MI, USA. mlu1@hfhs.org.
3
Department of Health Policy and Health Services Research, Henry Ford Health, Detroit, MI, USA.
4
Department of Public Health Sciences, Henry Ford Health, One Ford Place, Detroit, MI, 48202, USA.
5
Center for Integrated Health Care Research, Kaiser Permanente Hawaii, Honolulu, HI, USA.
6
Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA.
7
Department of Gastroenterology and Hepatology, Henry Ford Health, Detroit, MI, USA.
8
School of Medicine, Wayne State University, Detroit, MI, USA.
PMID:
38598114
PMCID:
PMC11133160
DOI:
10.1007/s12325-024-02858-1
No abstract available
Publication types
Published Erratum